Health sciences and technology are on the brink of a significant evolution, much of which may be accredited to the minds at institutions like MIT and Harvard. One such innovator is Louis DeRidder, who, after a life-threatening medical situation at age 12, dedicated his life to improving medical care. DeRidder's journey into drug delivery technologies began in high school and led him to transfer to Johns Hopkins University, where he proposed research on a nanoparticle-drug conjugate for brain cells, eyeing the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson’s, according to MIT News.
DeRidder's work now includes a groundbreaking project under the joint Harvard-MIT Health Sciences and Technology program. The project, named CLAUDIA, is designed to optimally dose chemotherapy drugs by measuring concentration in the blood and adjusting the infusion rate accordingly. The goal is to personalize drug dosing, a leap forward from a century-old formula based solely on body surface area estimations. "Once my advisors presented the reality of how chemotherapies are dosed," DeRidder said, "I thought, 'This is insane. How is this the clinical reality?'" This statement he told MIT News encapsulates the motivation behind his PhD project.
CLAUDIA’s development has been greatly aided by MathWorks fellowships and a National Science Foundation Graduate Research Fellowship received by DeRidder. This financial support helped refine the closed-loop drug delivery system through countless simulations using MATLAB and Simulink software. "MathWorks and Simulink are key to what we do," DeRidder emphasized in his interview with MIT News, highlighting the importance of technology in revolutionizing drug delivery.
Apart from CLAUDIA, DeRidder is also working on another significant project: developing new nanoparticles to quickly deliver therapeutic nucleic acids. Bridging the gap from medical devices to molecular therapies, DeRidder hopes to make a powerful impact on medicine. Despite his intensive research schedule, he finds time to serve his community, from mentoring students to aiding the homeless. "It’s easy to lose track of the concrete, simple ways that we can serve our communities when we’re doing research," DeRidder told MIT News, reminding that the objective of his work is ultimately to serve society. The pursuit of these goals leads him back to his roots, where he plans to focus on developing treatments for neurological diseases, driven by his high school experience with dementia and neurology patients.
Louis DeRidder's innovative approach to drug delivery not only embodies the advancements in medical science but also the compassion that fuels such breakthroughs. As DeRidder aims to push CLAUDIA toward clinical use and perhaps lay the foundation for a new company to commercialize it, the healthcare industry may soon witness a significant enhancement in drug administration safety and efficacy. His story is not just about technological achievement but also about the human desire “to help push it toward the clinic”, an aspiration which he confided to MIT News.
